Trop-2 in Upper Tract Urothelial Carcinoma
Trophoblast cell surface antigen 2 (Trop-2, encoded by <i>TACSTD2</i>) is the target protein of sacituzumab govitecan, a novel antibody-drug conjugate for locally advanced or metastatic urothelial carcinoma. However, the expression status of Trop-2 in upper tract urothelial carcinoma (UT...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/29/6/312 |
| Summary: | Trophoblast cell surface antigen 2 (Trop-2, encoded by <i>TACSTD2</i>) is the target protein of sacituzumab govitecan, a novel antibody-drug conjugate for locally advanced or metastatic urothelial carcinoma. However, the expression status of Trop-2 in upper tract urothelial carcinoma (UTUC) remains unclear. We performed immunohistochemical analysis of 99 UTUC samples to evaluate the expression status of Trop-2 in patients with UTUC and analyze its association with clinical outcomes. Trop-2 was positive in 94 of the 99 UTUC samples, and high Trop-2 expression was associated with favorable progression-free survival (PFS) and cancer-specific survival (<i>p</i> = 0.0011, 0.0046). Multivariate analysis identified high Trop-2 expression as an independent predictor of favorable PFS (all cases, <i>p</i> = 0.045; high-risk group (pT3≤ or presence of lymphovascular invasion or lymph node metastasis), <i>p</i> = 0.014). Gene expression analysis using RNA sequencing data from 72 UTUC samples demonstrated the association between high <i>TACSTD2</i> expression and favorable PFS (all cases, <i>p</i> = 0.069; high-risk group, <i>p</i> = 0.029). In conclusion, we demonstrated that Trop-2 is widely expressed in UTUC. Although high Trop-2 expression was a favorable prognostic factor in UTUC, its widespread expression suggests that sacituzumab govitecan may be effective for a wide range of UTUC. |
|---|---|
| ISSN: | 1198-0052 1718-7729 |